Latest Breaking News On - Cognition discovery foundation - Page 1 : comparemela.com

The Solution to a Common and Hazardous Symptom of BPD?

Recent research highlighted the potential role of an atypical antipsychotic to treat anxiety a prevalent and undertreated symptom in BPD that comes without the typical metabolic side effects.

United statesColorado springsNew jerseyUniversity of washingtonNew yorkRichard priceJoseph cerimeleRoger mcintyreInternational clinical psychopharmacologyWeill cornell medical collegeNeuroscience education instituteHackensack meridian school of medicineDrug administrationDivision of population healthUniversity of torontoBipolar support alliance

Novel kappa opioid receptor antagonist navacaprant significantly reduces depression symptoms: Phase II study

USA: Navacaprant, a new once-daily kappa opioid receptor antagonist, may cause a significant reduction of depression and anhedonia symptoms in participants with moderate-to-severe major depressive.

United statesAsia pacificPaull bernsSanjayj mathewRogers mcintyreBaylor college of medicineCognition discovery foundationNeumora therapeutics incUniversity of torontoDrug administrationDepression rating scaleSnaith hamilton pleasure scaleNew drug applicationBaylor collegeBlackthorn therapeuticsHamilton rating scale

Efficacy of novel drug proven in MDD study

Efficacy of novel drug proven in MDD study
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesRogers mcintyreSanjayj mathewCognition discovery foundationBaylor college of medicineUniversity of torontoExecutive directorHamilton rating scaleHamilton pleasure scaleVice chairBaylor collegeBlackthorn therapeuticsDepression rating scaleSnaith hamilton pleasure scaleAsia pacific

Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder

Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPaull bernsSanjayj mathewRogers mcintyreAsia pacificHelen rubinsteinCognition discovery foundationBaylor college of medicineUniversity of torontoNeumora therapeutics incDrug administrationNew drug applicationDepression rating scaleSnaith hamilton pleasure scaleBaylor collegeBlackthorn therapeutics

Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesNew yorkRoger mcintyreHerriot tabuteauMark jacobsonUniversity of torontoAxsome therapeutics incCognition discovery foundationAmerican society of clinical psychopharmacologyDrug administrationAmerican societyClinical psychopharmacologyExecutive directorDepression rating scaleChief executive officerAnhedonic symptoms